Kelso & Co and Juggernaut Capital Partners, the private equity backers of Foundation Consumer Healthcare, are considering a potential sale of the company with a price tag of up to $4bn, according to a report by Bloomberg.
Kelso & Co and Juggernaut Capital Partners, the private equity backers of Foundation Consumer Healthcare, are considering a potential sale of the company with a price tag of up to $4bn, according to a report by Bloomberg.
The report cites unnamed sources as revealing that the company, which produces the popular morning-after pill Plan B One-Step and over-the-counter brands including Breathe Right nasal strips, cold sore treatment Campho-Phenique, and Dimetapp cold medicine, is expected to draw interest from consumer health companies and private equity firms.
While the PE firms are reportedly working with financial advisers on a potential sale, the process is at an early stage there’s no certainty that a deal will happen, according to Bloomberg’s sources.
